Wasting Research - The Body

DO. SEE. HEAR. KNOW. Visit TheBody.com's 2008 World AIDS Day Center >>

BROWSE TOPICS IN LIVING WITH HIV:

Living With HIV: Home Page

Beyond Medications: Healthy Living for HIVers

Artistic Expression

Columns

Death and Mourning

Diet and Nutrition

Financial Issues

Inspiring Stories

Legal Issues

Mental Health

Religion

Workplace Issues

Wasting Research

General Research | Facial Wasting Treatment Research

General Research

Interventions for Fat Changes: New Research on Glitazones, Metformin and Testosterone (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Moderate Weight Loss Increasingly Common for HIVers on HAART (September 1, 2005)
Wasting syndrome may be on the decline, but moderate weight loss -- of 5% or more -- has increased steadily since 1995, and appears unrelated to lipodystrophy.
From aidsmap.com
Rosiglitazone Linked to Benign Tumors in Man With Lipodystrophy (August 17, 2004)
A case report ties the use of rosiglitazone, an experimental treatment for lipodystrophy-related fat loss, to the development of lipomas in one HIV-infected person.
From aidsmap.com
Rosiglitazone Reduces Lipoatrophy, Hyperinsulinemia in HIV-Infected Patients, Study Finds (May 19, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Predicting Lipoatrophy After Treatment Initiation (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Improvement in Lipoatrophy Associated With Highly Active Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Patients Switched from Stavudine to Abacavir or Zidovudine: The Results of the TARHEEL Study (January 15, 2004)
When people who had developed lipoatrohpy while taking d4T (stavudine, Zerit) switched to abacavir (Ziagen) or AZT (zidovudine, Retrovir), their condition improved.
In Clinical Infectious Diseases
In HIV Patients With Lipoatrophy, Antioxidants Lead to Only Modest Improvement in LDL Cholesterol (August 15, 2003)
From aidsmap.com
FRAM Study Finds a Lack of Association Between Lipoatrophy and Central Fat Gain (July 15, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Current Research on the Mechanisms Causing Lipoatrophy and Potential Treatments (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Rosiglitazone May Be Effective in Increasing Body Fat in Patients With Fat Wasting (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Substituting AZT or Abacavir for d4T in Patients With Lipoatrophy (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Serostim Study Initiated (Spring 2001)
In CRIA Update, from AIDS Community Research Initiative of America
Thalidomide Pharmacokinetics, Safety and Effect on HIV Viral Load and Immune Parameters (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Hormones and Body Composition (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
Exercise and HIV Wasting: From the Laboratory to the Clinic (July 2000)
In Body Positive, from Body Positive
The Use of Testosterone in AIDS Wasting Syndrome (May 3, 1999)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
The Changing Face of Malnutrition and HIV (April 22-25, 1999)
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
Treating HIV-Associated Weight Loss and Wasting (April 22-25, 1999)
In The 3rd International Conference on Nutrition and HIV Infection, from The Body PRO
Anabolic Steroids, Exercise and Wasting (April 1999)
In GMHC Treatment Issues, from Gay Men's Health Crisis
The Effects of Oxandralone on Body Weight and Composition in Patients With HIV-Associated Weight Loss (July 2, 1998)
In The 12th International AIDS Conference, from The Body PRO
HIV-Related Clinical Updates: Wasting/Endocrine Disorders (May 2, 1998)
In The 8th Clinical Care Options for HIV Symposium, from The Body PRO
Diagnosis and Treatment of Endocrine Disorders in the HIV-Infected Patient (February 1998)
In Journal of the International Association of Physicians in AIDS Care, from International Association of Physicians in AIDS Care
Metabolic Disturbances in HIV Infection Find Friend Not Foe in Protease Inhibitor Regimens (August 1997)
In TAGline, from Treatment Action Group
Anabolic Steroid Boosts Weight (September 1996)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Wasting Syndrome: Oral Oxandrolone Re-Released in U.S. (December 22, 1995)
In AIDS Treatment News, from AIDS Treatment News

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.